Knowles R C, Gilmore B
Am J Clin Pathol. 1983 Oct;80(4 Suppl):603-8.
Over a 12-month period, between July 1981 and June 1982, 115 active participants in the Microbiology program of the College of American Pathologists Quality Assurance Service (QAS) submitted a total of 555,619 individual determinations on three quality control reference strains using the NCCLS standardized disc diffusion procedure. Data is presented for those antimicrobic agent/reference strain combinations for which NCCLS control limits have been changed since the last report of QAS microbiology data or that continue to show discrepancies with current NCCLS individual daily test control guidelines. Data for Escherichia coli versus cefoxitin, doxycycline, and nalidixic acid and for Staphylococcus aureus versus cefoxitin, nafcillin, and oxacillin show good compliance with the new NCCLS guidelines and distributions that are all approximately Gaussian. Significant discrepancies were noted for six combinations; cefamandole, cephalothin, neomycin, and nitrofurantoin versus E. coli and amikacin and clindamycin versus S. aureus. Of these discrepancies, only neomycin/E. coli and amikacin/S. aureus can be accounted for by a subpopulation of laboratories, which, when removed, corrects the data.
在1981年7月至1982年6月的12个月期间,美国病理学家学会质量保证服务(QAS)微生物学项目的115名活跃参与者使用NCCLS标准化纸片扩散法,对三种质量控制参考菌株进行了总共555,619次个体测定。本文给出了那些自QAS微生物学数据上次报告以来NCCLS控制限已更改,或继续与当前NCCLS个体每日测试控制指南存在差异的抗菌剂/参考菌株组合的数据。大肠杆菌与头孢西丁、强力霉素和萘啶酸以及金黄色葡萄球菌与头孢西丁、萘夫西林和苯唑西林的数据显示,与新的NCCLS指南具有良好的一致性,且分布均近似高斯分布。六种组合存在显著差异;头孢孟多、头孢噻吩、新霉素和呋喃妥因与大肠杆菌,以及阿米卡星和克林霉素与金黄色葡萄球菌。在这些差异中,只有新霉素/大肠杆菌和阿米卡星/金黄色葡萄球菌可以由一部分实验室来解释,去除这部分实验室后,数据就会得到纠正。